EBioMedicine (Nov 2016)

Inhibition of G0/G1 Switch 2 Ameliorates Renal Inflammation in Chronic Kidney Disease

  • Naoya Matsunaga,
  • Eriko Ikeda,
  • Keisuke Kakimoto,
  • Miyako Watanabe,
  • Naoya Shindo,
  • Akito Tsuruta,
  • Hisako Ikeyama,
  • Kengo Hamamura,
  • Kazuhiro Higashi,
  • Tomohiro Yamashita,
  • Hideaki Kondo,
  • Yuya Yoshida,
  • Masaki Matsuda,
  • Takashi Ogino,
  • Kazutaka Tokushige,
  • Kazufumi Itcho,
  • Yoko Furuichi,
  • Takaharu Nakao,
  • Kaori Yasuda,
  • Atsushi Doi,
  • Toshiaki Amamoto,
  • Hironori Aramaki,
  • Makoto Tsuda,
  • Kazuhide Inoue,
  • Akio Ojida,
  • Satoru Koyanagi,
  • Shigehiro Ohdo

DOI
https://doi.org/10.1016/j.ebiom.2016.10.008
Journal volume & issue
Vol. 13, no. C
pp. 262 – 273

Abstract

Read online

Chronic kidney disease (CKD) is a global health problem, and novel therapies to treat CKD are urgently needed. Here, we show that inhibition of G0/G1 switch 2 (G0s2) ameliorates renal inflammation in a mouse model of CKD. Renal expression of chemokine (C-C motif) ligand 2 (Ccl2) was increased in response to p65 activation in the kidneys of wild-type 5/6 nephrectomy (5/6Nx) mice. Moreover, 5/6Nx Clk/Clk mice, which carry homozygous mutations in the gene encoding circadian locomotor output cycles kaput (CLOCK), did not exhibit aggravation of apoptosis or induction of F4/80-positive cells. The renal expression of G0s2 in wild-type 5/6Nx mice was important for the transactivation of Ccl2 by p65. These pathologies were ameliorated by G0s2 knockdown. Furthermore, a novel small-molecule inhibitor of G0s2 expression was identified by high-throughput chemical screening, and the inhibitor suppressed renal inflammation in 5/6Nx mice. These findings indicated that G0s2 inhibitors may have applications in the treatment of CKD.

Keywords